Synthetic peptide lowers Alzheimer's-linked amyloid beta in mouse and cell studies
Researchers designed a synthetic peptide, P33, that reduced amyloid beta production in cultured neurons and in a mouse model of Alzheimer's disease. The molecule works by selectively slowing the activity of BACE1, an enzyme that cuts another protein to create amyloid beta, rather than blocking the enzyme completely. The team suggests this approach may avoid side effects seen with earlier BACE1 inhibitors, though further testing is needed.
BACE1 acts like molecular scissors, cutting a precursor protein to generate amyloid beta. Earlier drugs that fully blocked this enzyme failed in trials, partly because BACE1 also performs other needed tasks. To avoid that, researchers created chemically modified short peptides that resist rapid breakdown and can enter cells.
From a 50-molecule library, P33 emerged as the standout in cultured neurons. It cut amyloid beta release by more than half and reduced BACE1-linked activity over 50%, while leaving BACE2 largely unaffected. In a mouse model, eight weeks of treatment lowered brain amyloid beta and plaque area in the cortex and hippocampus by 35.6%, without detected organ damage or inflammation-marker changes.
People with Alzheimer’s disease, their families, and caregivers could be affected if this peptide approach eventually translates into safer treatments. By partially modulating BACE1 rather than shutting it down, P33 may reduce amyloid beta while avoiding some side effects that limited earlier inhibitors. However, these are early cell and mouse findings; whether the strategy helps human patients, and at what cost or accessibility, remains unknown. Researchers and drug developers may see it as a promising platform for further study.